Erratum: Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma caki cells through down-regulation of p53-Dependent Bcl-2 expression and inhibition of Mcl-1 Protein Stability (PLoS ONE (2014) 9:4 (e95588) DOI 10.1371/journal.pone.0095588);Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Seo, Bo Ram ^a   Min, Kyoung Jin ^a   Cho, Il Je ^b   Kim, Sang Chan ^b   Kwon, Taeg Kyu ^a  

^a Keimyung University   (South Korea)

^b Daegu Haany University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; DACTOLISIB; MESSENGER RNA; PIFITHRIN ALPHA; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUINOLINE DERIVATIVE; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; RHIZOME; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; DNA FRAGMENTATION; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84899728380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151886     Document Type: Erratum

References (67)

1. Sun X, Huang J, Homma T, Kita D, Klocker H, et al. (2009) Genetic alterations in the PI3K pathway in prostate cancer. Anticancer research 29: 1739-1743.
2. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, et al. (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proceedings of the National Academy of Sciences of the United States of America 96: 1563-1568. (Pubitemid 29098491)
3. Tang JM, He QY, Guo RX, Chang XJ (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung cancer 51: 181-191.
4. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464. (Pubitemid 41637985)
5. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. (Pubitemid 46799492)
6. Lim KH, Counter CM (2005) Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer cell 8: 381-392. (Pubitemid 41579833)
7. Gao N, Zhang Z, Jiang BH, Shi X (2003) Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochemical and biophysical research communications 310: 1124-1132. (Pubitemid 37237653)
8. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, et al. (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857. (Pubitemid 39093031)
9. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, et al. (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer research 71: 3246-3256.
10. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH (2006) Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cellular signalling 18: 2262-2271. (Pubitemid 44636166)
11. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484. (Pubitemid 43199434)
12. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137. (Pubitemid 44466632)
13. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, et al. (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. The Biochemical journal 405: 513-522. (Pubitemid 47172049)
14. Martin J, Masri J, Bernath A, Nishimura RN, Gera J (2008) Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochemical and biophysical research communications 372: 578-583.
15. Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 2278-2287.
16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England journal of medicine 356: 2271-2281. (Pubitemid 46849157)
17. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
18. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508. (Pubitemid 43259931)
19. Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, et al. (2006) The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66: 5130-5142. (Pubitemid 43844935)
20. Loeb S, Roehl KA, Catalona WJ, Nadler RB (2007) Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177: 899-902. (Pubitemid 46223578)
21. Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, et al. (2011) Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med 9: 133-142.
22. Ng SS, Tsao MS, Nicklee T, Hedley DW (2001) Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 7: 3269-3275. (Pubitemid 32963853)
23. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, et al. (2003) Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56: 846-853. (Pubitemid 36677381)
24. Santoni M, Pantano F, Amantini C, Nabissi M, Conti A, et al. (2014) Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochim Biophys Acta 1845: 221-231.
25. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphati-dylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
26. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, et al. (2010) Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer research 70: 8097-8107.
27. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, et al. (2010) Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115: 559-569.
28. Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T (2011) Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncology reports 26: 1273-1279.
29. Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, et al. (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer 10: 90-101.
30. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, et al. (2010) The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638.
31. Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30: 85-94.
32. Gescher A (2004) Polyphenolic phytochemicals versus non-steroidal anti-inflammatory drugs: which are better cancer chemopreventive agents? J Chemother 16 Suppl 4: 3-6. (Pubitemid 40065270)
33. Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE, et al. (2012) Curcumin-from molecule to biological function. Angew Chem Int Ed Engl 51: 5308-5332.
34. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, et al. (2003) Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24: 1199-1208.
35. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S (1999) Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clinical immunology 93: 152-161. (Pubitemid 29523391)
36. Chen H, Zhang ZS, Zhang YL, Zhou DY (1999) Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer research 19: 3675-3680.
37. Moragoda L, Jaszewski R, Majumdar AP (2001) Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer research 21: 873-878. (Pubitemid 32494183)
38. Pal S, Choudhuri T, Chattopadhyay S, Bhattacharya A, Datta GK, et al. (2001) Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells. Biochemical and biophysical research communications 288: 658-665. (Pubitemid 33030080)
39. Bush JA, Cheung KJ, Jr., Li G (2001) Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Experimental cell research 271: 305-314. (Pubitemid 33141212)
40. Bharti AC, Donato N, Singh S, Aggarwal BB (2003) Curcumin (diferuloyl-methane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062. (Pubitemid 36139379)
41. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, et al. (2003) Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2: 95-103.
42. Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, et al. (2005) Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26: 1905-1913. (Pubitemid 41631263)
43. Gao X, Deeb D, Jiang H, Liu YB, Dulchavsky SA, et al. (2005) Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria. J Exp Ther Oncol 5: 39-48. (Pubitemid 41076989)
44. Sandur SK, Deorukhkar A, Pandey MK, Pabon AM, Shentu S, et al. (2009) Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys 75: 534-542.
45. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, et al. (2008) Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res 14: 2128-2136. (Pubitemid 351551125)
46. Vinod BS, Antony J, Nair HH, Puliyappadamba VT, Saikia M, et al. (2013) Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis 4: e505.
47. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, et al. (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861. (Pubitemid 46762173)
48. Tallarida RJ (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-872. (Pubitemid 32761897)
49. Xu CX, Zhao L, Yue P, Fang G, Tao H, et al. (2011) Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 12: 549-555.
50. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, et al. (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106: 22299-22304.
51. Zhong Q, Gao W, Du F, Wang X (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121: 1085-1095. (Pubitemid 40884398)
52. Groll M, Huber R (2003) Substrate access and processing by the 20S proteasome core particle. Int J Biochem Cell Biol 35: 606-616. (Pubitemid 36369509)
53. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, et al. (1988) Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7: 123-131.
54. Wilson BE, Mochon E, Boxer LM (1996) Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 16: 5546-5556. (Pubitemid 26315074)
55. Heckman CA, Wheeler MA, Boxer LM (2003) Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 22: 7891-7899. (Pubitemid 37175853)
56. Heckman CA, Mehew JW, Boxer LM (2002) NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21: 3898-3908. (Pubitemid 34620858)
57. Chen HM, Boxer LM (1995) Pi 1 binding sites are negative regulators of bcl-2 expression in pre-B cells. Mol Cell Biol 15: 3840-3847.
58. Heckman C, Mochon E, Arcinas M, Boxer LM (1997) The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas. J Biol Chem 272: 19609-19614. (Pubitemid 27337765)
59. Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135. (Pubitemid 24208916)
60. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ (2002) Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1: 989-997.
61. Stein RC (2001) Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 8: 237-248. (Pubitemid 32947646)
62. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
63. Doghman M, Lalli E (2012) Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. Mol Cell Endocrinol 364: 101-104.
64. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, et al. (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10-13.
65. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, et al. (2002) Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 11: 535-540. (Pubitemid 34615160)
66. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, et al. (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356. (Pubitemid 28234275)
67. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, et al. (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 58: 516-527.